II. AMENDMENT TO THE CLAIMS

1-15. (Canceled)

16. (Previously Presented) A method of enhancing apoptosis of a target cell by administering a therapeutically effective amount of an immunoconjugate to a subject, wherein said immunoconjugate comprises an anti-CD20 antibody or an immunogenic fragment thereof that binds to CD20 expressed by a target cell that is to be eradicated, wherein said anti-CD20 antibody or immunogenic fragment thereof possesses human effector function, and further wherein said anti-CD20 antibody or immunogenic fragment thereof is fused at its carboxy terminus to interferon-α-2a (IFN- α-2a) that binds a receptor expressed on the surface of an effector cell.

17. (Previously Presented) The method of claim 16, wherein the target cell is a B cell lymphoma cell.

18-22. (Canceled)

23. (Previously Presented) The method of claim 16, wherein the effector cell is a cell which expresses an IFN- α-2a receptor selected from the groups consisting of natural killer (NK) cells, lymphocyte-activated killer (LAK) cells, macrophages, monocytes, and polymorphonuclear (PMN) cells.

24. (Previously Presented) The method of claim 16, wherein said immunoconjugate facilitates extracellular (ADCC-type) and/or intracellular (phagocytic) killing of target cell.

25. (Currently Amended) The method of claim 16, wherein said immunoconjugate comprises an anti-CD20 antibody or an immunogenic fragment thereof selected from the group consisting of ~~Rituximab~~ rituximab (RITUXAN®), 1F5, ~~Ibritumomab~~ ibritumomab (ZEVALIN®), 1H4, and anti-B1 (BEXXAR®) antibody.

26. (Previously Presented) The method of claim 16, wherein the immunogenic fragment is selected from the group consisting of a single variable region of the anti-CD20 antibody VL or VH, two or more variable regions, domain deleted antibody and minibodies, Fab, Fab1, Fab2, SFV, and single chain antibodies.

27. (Previously Presented) The method of claim 16, wherein the anti-CD20 antibody or immunogenic fragment is a humanized or chimeric antibody.